<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007289</url>
  </required_header>
  <id_info>
    <org_study_id>P170916J</org_study_id>
    <nct_id>NCT04007289</nct_id>
  </id_info>
  <brief_title>Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension</brief_title>
  <acronym>APIS</acronym>
  <official_title>Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrahepatic non-cirrhotic portal hypertension (INCPH) is a rare disease mostly affecting&#xD;
      adults in their forties, characterized by portal hypertension related to alterations of&#xD;
      intrahepatic microcirculation in the absence of cirrhosis.The only therapeutic options&#xD;
      currently available for patients with INCPH include prophylaxis for variceal bleeding using&#xD;
      betablockers and/or endoscopic band ligation and TIPSS (transjugular intrahepatic&#xD;
      portosystemic shunt) or liver transplantation for severe cases.&#xD;
&#xD;
      The investigators hypothesize that anticoagulation using Apixaban in patients with INCPH&#xD;
      might prevent occurrence or extension of portal, splenic or mesenteric veins thromboses and&#xD;
      thus the development of chronic portal vein thrombosis and associated complications, but also&#xD;
      avoid intrahepatic thromboses and consequently liver disease progression and variceal&#xD;
      bleeding.&#xD;
&#xD;
      The Primary Objective is to evaluate the effect of 24 months low dosing of apixaban (2.5 mg x&#xD;
      2/day) versus placebo on the occurrence or the extension of portal venous system thrombosis&#xD;
      (including splenic, mesenteric veins, portal trunk or left or right portal branches) at 24&#xD;
      months in patients with INCPH.&#xD;
&#xD;
      166 patients will be included in 16 centers in a prospective, national multicentric, phase&#xD;
      III, superiority comparative randomized (1:1) double-blinded clinical trial with two parallel&#xD;
      arms: apixaban versus placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrahepatic non-cirrhotic portal hypertension (INCPH) is a rare disease mostly affecting&#xD;
      adults in their forties, characterized by portal hypertension related to alterations of&#xD;
      intrahepatic microcirculation in the absence of cirrhosis.The only therapeutic options&#xD;
      currently available for patients with INCPH include prophylaxis for variceal bleeding using&#xD;
      betablockers and/or endoscopic band ligation and TIPSS (transjugular intrahepatic&#xD;
      portosystemic shunt) or liver transplantation for severe cases.&#xD;
&#xD;
      The investigators hypothesize that anticoagulation using Apixaban in patients with INCPH&#xD;
      might prevent occurrence or extension of portal, splenic or mesenteric veins thromboses and&#xD;
      thus the development of chronic portal vein thrombosis and associated complications, but also&#xD;
      avoid intrahepatic thromboses and consequently liver disease progression and variceal&#xD;
      bleeding.&#xD;
&#xD;
      The Primary Objective is to evaluate the effect of 24 months low dosing of apixaban (2.5 mg x&#xD;
      2/day) versus placebo on the occurrence or the extension of portal venous system thrombosis&#xD;
      (including splenic, mesenteric veins, portal trunk or left or right portal branches) at 24&#xD;
      months in patients with INCPH.&#xD;
&#xD;
      The Secondary Objectives are :&#xD;
&#xD;
        1. To assess the safety of apixaban on: (a) any major bleeding as defined by the ISTH&#xD;
           (International Society on Thrombosis and Haemostasis) guidelines; (b) liver toxicity;&#xD;
           (c) adverse events and reactions.&#xD;
&#xD;
        2. To compare the effect of 24 months low dosing of apixaban (2.5 mg x 2/day) versus&#xD;
           placebo on the following outcomes, assessed during the 24 months of treatment:&#xD;
&#xD;
             1. - at least one event among: deep vein thrombosis in any location, arterial&#xD;
                thrombosis, major bleeding, death&#xD;
&#xD;
             2. - the occurrence of deep vein thrombosis in any location or arterial thrombosis&#xD;
&#xD;
             3. - mortality (global, liver related, non-liver related), and mortality or liver&#xD;
                transplantation&#xD;
&#xD;
             4. - each and any event among: liver decompensation, complications of portal&#xD;
                hypertension including portal hypertensive related gastrointestinal bleeding, liver&#xD;
                transplantation or death;&#xD;
&#xD;
             5. - portal hypertension related features (spleen size, platelet count, size of&#xD;
                esophageal varices, portal blood flow velocity) and markers of bacterial&#xD;
                translocation and inflammation&#xD;
&#xD;
             6. - liver function&#xD;
&#xD;
             7. - quality of life&#xD;
&#xD;
        3. To evaluate the effect of 24 months low dosing of apixaban (2.5 mg x 2/day) versus&#xD;
           placebo on the occurrence or the extension of portal venous system thrombosis (including&#xD;
           splenic, mesenteric veins, portal trunk or left or right portal branches) at 24 months&#xD;
           after randomisation in patients with INCPH according to HIV status&#xD;
&#xD;
        4. To identify predictors of portal venous system thrombosis and liver related events:&#xD;
&#xD;
             -  in the control group: liver and spleen stiffness; portal blood flow velocity;&#xD;
                specific coagulation tests; markers of bacterial translocation and inflammation&#xD;
&#xD;
             -  in the group receiving apixaban: plasma apixaban levels&#xD;
&#xD;
        5. To assess treatment compliance&#xD;
&#xD;
        6. To study the occurrence or extension of portal venous system thrombosis or occurrence of&#xD;
           deep vein thrombosis in any location or arterial thrombosis in the 6 months after the&#xD;
           24-month treatment with apixaban versus placebo.&#xD;
&#xD;
      166 patients will be included in 16 centers in a prospective, national multicentric, phase&#xD;
      III, superiority comparative randomized (1:1) double-blinded clinical trial with two parallel&#xD;
      arms: apixaban versus placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will be a prospective, national multicentric, phase III, superiority comparative randomized (1:1) double-blinded clinical trial with two parallel arms: apixaban versus placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Portal venous system thrombosis</measure>
    <time_frame>24 months</time_frame>
    <description>Occurrence or extension of portal venous system thrombosis (including splenic, mesenteric veins, portal trunk or left or right portal branches) at 24 months in patients with INCPH.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of side effects</measure>
    <time_frame>24 months</time_frame>
    <description>Any major bleeding as defined by the International Society on Thrombosis and Haemostasis guidelines; liver toxicity; adverse events and reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint including thrombosis and major bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Cumulative incidence of one event among: deep vein thrombosis in any location, arterial thrombosis, major bleeding, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of vein or arterial thrombosis</measure>
    <time_frame>24 months</time_frame>
    <description>Compare the effect of 24 months low dosing of apixaban (2.5 mg x 2/day) versus placebo on one event among: deep vein thrombosis in any location, arterial thrombosis,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality or liver transplantation</measure>
    <time_frame>24 months</time_frame>
    <description>cumulative incidence of death (global, liver related, non liver related) or liver transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of liver disease</measure>
    <time_frame>24 months</time_frame>
    <description>cumulative incidence of liver decompensation, complications of portal hypertension including portal hypertensive related gastrointestinal bleeding, liver transplantation or death;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portal hypertension related features</measure>
    <time_frame>24 months</time_frame>
    <description>change in size of oesophageal varices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portal hypertension related features</measure>
    <time_frame>24 months</time_frame>
    <description>platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of bacterial translocation and inflammation</measure>
    <time_frame>24 months</time_frame>
    <description>circulating concentrations of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>24 months</time_frame>
    <description>change in child pugh score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>24 months</time_frame>
    <description>change in MELD score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>change in quality of life assessed using SF36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of quality life</measure>
    <time_frame>24 months</time_frame>
    <description>change in quality of life assessed using CLDQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence or the extension of portal venous system thrombosis at 24 months after randomisation in patients with INCPH according to HIV status</measure>
    <time_frame>24 months</time_frame>
    <description>Compare the effect of 24 months low dosing of apixaban (2.5 mg x 2/day) versus placebo on the occurrence or the extension of portal venous system thrombosis (including splenic, mesenteric veins, portal trunk or left or right portal branches) at 24 months after randomisation in patients with INCPH according to HIV status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictors of portal venous system thrombosis and liver related events</measure>
    <time_frame>24 months</time_frame>
    <description>In group receiving Apixaban : plasma Apixaban levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictors of portal venous system thrombosis and liver related events</measure>
    <time_frame>24 months</time_frame>
    <description>in the control group : portal blood flow Velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictors of portal venous system thrombosis and liver related events</measure>
    <time_frame>24 months</time_frame>
    <description>in the control group : stiffness measured using Fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictors of portal venous system thrombosis and liver related events</measure>
    <time_frame>24 months</time_frame>
    <description>in the control group : levels of specific coagulation tets (D-dimeres)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment compliance</measure>
    <time_frame>24 months</time_frame>
    <description>number of compliant patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence or extension of portal venous system thrombosis or occurrence of deep vein thrombosis in any location or arterial thrombosis in the 6 months after the 24-month treatment with apixaban versus placebo</measure>
    <time_frame>30 months</time_frame>
    <description>cumulative incidence of extension of portal venous system thrombosis or deep vein thrombosis in any location or arterial thrombosis in the 6 months after the 24-month treatment with apixaban versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Intrahepatic Non Cirrhotic Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>APIXABAN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apixaban, 1 pill of 2.5 mg per os twice a day (one in the morning and one in the evening) for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 1 pill per os twice a day (one in the morning and one in the evening) for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Administration of Apixaban ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography, Biological samples collections to identify predictors of thrombosis and liver related events</description>
    <arm_group_label>APIXABAN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 and ≤ 90 year old male and female patients,&#xD;
&#xD;
          -  For child-bearing aged women, contraception using progestatives, or intrauterine&#xD;
             device or mechanical contraception&#xD;
&#xD;
          -  Adequate prophylaxis against variceal bleeding according to EASL (European association&#xD;
             for the study of the liver) guidelines&#xD;
&#xD;
          -  Intrahepatic non cirrhotic portal hypertension (INCPH), defined according to the&#xD;
             recent VALDIG workshop (Feb. 2017, Ascona, Italy) as having one of the following&#xD;
             simultaneous associations:&#xD;
&#xD;
               1. absence of cirrhosis on an adequate liver biopsy, and one or more signs specific&#xD;
                  for portal hypertension&#xD;
&#xD;
               2. absence of cirrhosis on an adequate liver biopsy, and one or more signs not&#xD;
                  specific for portal hypertension and one or more histological signs for INCPH&#xD;
&#xD;
               3. in the absence of adequate liver biopsy, 2 reliable liver stiffness values&#xD;
                  determined using transient elastography (Fibroscan) &lt; 10 kPa and one or more&#xD;
                  signs specific for portal hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myeloproliferative disease treated with aspirin to prevent vascular events, paroxysmal&#xD;
             nocturnal hemoglobinuria.&#xD;
&#xD;
          -  Ongoing oestroprogestative contraception&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Complete thrombosis of superior mesenteric vein and/or inferior mesenteric vein&#xD;
&#xD;
          -  Complete portal vein thrombosis or portal cavernoma&#xD;
&#xD;
          -  Recent (&lt;6 months) partial portal venous system thrombosis&#xD;
&#xD;
          -  Mandatory indication or contraindication for anticoagulation according to guidelines&#xD;
             of the American college of chest physicians&#xD;
&#xD;
          -  Concomitant treatment with any other anticoagulant agent unless when bridging from one&#xD;
             to the other is performed&#xD;
&#xD;
          -  Disease at high risk of bleeding (except for portal hypertension)&#xD;
&#xD;
          -  Active clinically significant bleeding:. This may include current or recent&#xD;
             gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding,&#xD;
             recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent&#xD;
             intracranial haemorrhage, arteriovenous malformations, vascular aneurysms or major&#xD;
             intraspinal or intracerebral vascular abnormalities.&#xD;
&#xD;
          -  Platelet &lt; 40000/mm3, or prothrombin index &lt;40% in the absence of anti-vitamin K or&#xD;
             Factor V &lt; 40% or Fibrinogen &lt; 1.0g/L&#xD;
&#xD;
          -  Transjugular intrahepatic portosystemic shunt (TIPSS) or surgical portosystemic shunt&#xD;
&#xD;
          -  Participation in another interventional trial&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
          -  Hepatitis C with detectable HCV RNA at inclusion&#xD;
&#xD;
          -  Positive HBs Ag, except patients with HBeAg-negative chronic HBV infection, previously&#xD;
             termed 'inactive carriers' [characterised by the presence of serum antibodies to HBeAg&#xD;
             (anti-HBe), undetectable or low (&lt;2,000 IU/mL) HBV DNA levels and normal serum ALT&#xD;
             levels] that can be included&#xD;
&#xD;
          -  Alcohol intake &gt;210 g/week for men and 140 g/week for women&#xD;
&#xD;
          -  Mandatory indication to aspirin or other antiplatelet agents including P2Y12 receptor&#xD;
             antagonists according to guidelines of the American Heart Association&#xD;
&#xD;
          -  Patient who underwent liver transplantation less than 3 years before screening&#xD;
&#xD;
          -  Severe hepatic impairment (Child-Pugh C) or significant active liver injury (serum ALT&#xD;
             level &gt; 5 times the upper limit of normal values)&#xD;
&#xD;
          -  Life expectancy &lt;12 months&#xD;
&#xD;
          -  Specific causes of portal hypertension or specific vascular liver diseases: history of&#xD;
             bone marrow transplantation, Budd-Chiari syndrome / hepatic venous outflow&#xD;
             obstruction, hepatic schistosomiasis diagnosed on liver biopsy (an isolated positive&#xD;
             serology is not an exclusion criterion), cardiac failure, Fontan surgery, Abernethy&#xD;
             syndrome, Hereditary hemorrhagic telangiectasia, chronic cholestatic diseases, liver&#xD;
             infiltration by tumor cells&#xD;
&#xD;
          -  Concomitant use of potent inhibitors of CYP3A4 or P-gp. In case of moderate&#xD;
             interactions with apixaban (for example, immunosuppressive treatment), the dose of&#xD;
             CYP3A4 inhibitor will be adapted according to its plasmatic level in the study&#xD;
             patient.&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients including&#xD;
             lactose.&#xD;
&#xD;
          -  Patients unable to give consent (under guardianship or curatorship)&#xD;
&#xD;
          -  No written informed consent for participation in the study&#xD;
&#xD;
          -  No coverage for medical insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Emmanuel RAUTOU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Emmanuel RAUTOU</last_name>
    <phone>140875283</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-emmanuel.rautou@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique VALLA</last_name>
    <phone>140875283</phone>
    <phone_ext>+33</phone_ext>
    <email>dominique.valla@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beaujon hospital</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre emmanuel RAUTOU</last_name>
      <phone>1 40 87 50 00</phone>
      <phone_ext>33</phone_ext>
      <email>pierre-emmanuel.rautou@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

